Addition of micromolar concentrations of Riluzole, a putative glutamate receptor antagonist (GRM1) enhanced Wnt/β-catenin signaling, shown to decrease proliferation and increase the differentiation of melanoma cells in vitro when combined with exogenous Wnt3a [22]. Here, WNT3A is linked to melanoma.